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Abstract: 
Sepsis is a syndrome consisting of physiological, pathological and biochemical anomalies caused by infectious agents. 
It causes clinical organ dysfunction, which is identified by an acute increase in the Sequential (sepsis-related) Organ 
Failure Assessment (SOFA) score of two or more points. SOFA score is a score of three components that can be easily 
used at the bedside to track the clinical status of a patient while on admission, and these are altered respiratory rate 
of ≥ 22 breaths/minute, altered mental status, and systolic blood pressure of ≤ 100 mmHg. A patient with SOFA 
score of ≥ 2 has an attributable 2 - 25-fold increased risk of mortality compared to a patient with SOFA score of ˂ 2. 
This present review provides information on the new definition of sepsis and septic shock, aetiology, pathophysiology, 
biochemical, pathological and haematological changes, morbidity and mortality parameters, management, and 
prognostic factors in patients with sepsis. 
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Abstrait: 
La septicémie est un syndrome constitué d'anomalies physiologiques, pathologiques et biochimiques causées par des 
agents infectieux. Il provoque un dysfonctionnement des organes cliniques, qui est identifié par une augmentation 
aiguë du score d'évaluation séquentielle (liée à la septicémie) de la défaillance d'organe (SOFA) d'au moins deux 
points. Le score SOFA est un score de trois composants qui peuvent être facilement utilisés au chevet du patient pour 
suivre l'état clinique d'un patient lors de son admission, et il s'agit d'une fréquence respiratoire altérée ≥ 22 
respirations / minute, d'un état mental altéré et d'une pression artérielle systolique de ≤ 100 mmHg. Un patient avec 
un score SOFA ≥ 2 a un risque de mortalité attribuable 2 à 25 fois plus élevé qu'un patient avec un score SOFA de ˂ 
2. Cette revue fournit des informations sur la nouvelle définition de la septicémie et du choc septique, l'étiologie, la 
physiopathologie, changements biochimiques, pathologiques et hématologiques, paramètres de morbidité et de 
mortalité, prise en charge et facteurs pronostiques chez les patients atteints de septicémie. 
Mots clés: septicémie, choc septique, score SOFA, physiopathologie, faisceaux de prise en charge 





 Sepsis is a major public health concern 
at individual, health system and societal levels 
both in the developed and developing nations of 
the world (1). It is characterized by syndrome of 
physiological, pathological and biochemical ano- 
malies caused by infectious agents (2). The 
incidence of sepsis over the years is on the 
increase. About 49 million cases of sepsis and 
11 million sepsis-related deaths were reported 
globally in the year 2017 (3), which constitute 
about 20% of all deaths globally.   
 On annual basis, estimated 3 million and 
1.2 million cases of sepsis are reported globally 
among newborns and children respectively. 
About 30% of neonatal sepsis-related deaths 
are due to multidrug resistant organisms (4). 
The total cost of managing sepsis in the US 
hospitals in 2011 amounted to 20 billion US 
dollars, constituting 5% of US total hospital bill 
(3,5).      
 This present review provides informa- 
tion on the new definition of sepsis and septic 
shock; aetiology, biochemical, pathological and 
haematological changes in patients with sepsis, 
morbidity and mortality parameters, and mana- 
gement and prognostic factors of sepsis. 
Methodology:  
 Two electronic databases (PubMed and 
Google Scholar) were examined for list of publ- 
ications written in English Language relating to 
pathophysiology and management of sepsis. 
Additional publications were obtained from 
textbooks and other hardcopy journals. After 
removing duplicate and non-relevant publica- 
tions, a total of 87 publications were included for 
the review. Fig 1 depicts the process by which 
publications used for the review were selected.  
Pathophysiology of sepsis:  
 Sepsis is a condition of dysregulated 
host response that was ab-initio initiated to 
exterminate the invading pathogens into the 
body (6). The host response is mediated by the 
innate and adaptive immune systems. The 
various cell types including monocytes, macro 
phages, neutrophils, dendritic and epithelial 
cells involved in innate immune system possess 
pattern-recognition receptors (PRRs). The PRRs 
are essential for recognizing invading bacteria 
and subsequent initiation of immune response. 
They recognize both pathogen-associated mole- 
cular patterns (PAMPs) which are conserved 
motif expressed by pathogens and damage-
associated molecular patterns (DAMPs) also 
called alarmins, which are host cell molecules 
released during inflammatory stress (7).
 Following the invasion by the pathogen 
and its interaction with the host innate immune 
cells, there is a coordinated host response 
characterized by both proinflammatory and anti-
inflammatory/immunosuppressive reactions that 
are directed to eliminate the pathogens and 
restore normal homeostasis. When the pathogen 
 
Fig 1: Process for selection of articles for the review 




succeeds in circumventing the protective host 
immunity, there is continuous stimulation of 
host cells resulting in excessive and injurious 
immune response, and inability to restore 
homeostasis. This is exactly what transpired in 
a host with sepsis (4). 
Hyperinflammation 
Initiation of inflammation   
 The first line of defense against invading 
pathogens include the anatomical barriers such 
as the skin and mucosal lining of the respiratory, 
gastrointestinal and urogenital tracts. This is 
followed by interaction with the innate immune 
system that comprise of complement system, 
sentinel phagocytic cells, and natural killer cells, 
which serve to activate the adaptive immune 
system. The innate immune system broadly 
recognizes various antigens by sensing the 
carbohydrate and fatty acid molecules present 
on the surface of most pathogens, collectively 
known as pathogen associated molecular 
patterns (PAMPs) or host cell molecules 
expressed during inflammatory stress called 
damage associated molecular patterns (DAMPs). 
PAMPs or DAMPs bind to pattern-recognition 
receptors (PRRs) on the cells of these innate 
immune system resulting in signaling cascade 
that leads to sustained immune activation and 
dysfunction from hyperproduction of cytokines. 
The PRRs are grouped into various families such 
as Toll-like receptor (TLRs), C-lectin receptors 
(CLRs), retinoic acid-inducible gene-like (RAG) 
receptors, and nucleotide-binding oligomeri- 
zation domain-like (NOD) receptors (4). The 
most widely studied of the PRRs is the TLR. 
 In pathogenesis of sepsis, implicated 
proinflammatory cytokines include IL-1β, IL-12, 
IL-18, and TNF. Also involved are high mobility 
group box 1 (HMGB1), a nuclear protein actively 
secreted following inflammatory stimuli, and 
S100A8/9 (calprotectin), a heterodimer protein 
expressed in neutrophil. Both HMGB1 and 
S100A8/9 levels are elevated in sepsis. HMGB1 
can act as cytokine or chemotactic factor via 
TLR4 signaling while S100A8/9 stimulates 
systemic inflammation also via TLR signaling. If 
these processes are not curtailed promptly, and 
local response spread systemically, the TLR- 
signaling activation of the immune system will 
result in harmful hyperinflammatory response 
initiated by proinflammatory cytokines which is 
called the “cytokine-chemokine storm”. This is 
believed to be responsible for all the various 
consequences seen in early phase of sepsis, 
which has therefore been the target of many 
clinical trials with the use of antibodies or 
inhibitors of cytokines such as TNF-α and β, IL-
1β and other anti-inflammatory strategy (4,8). 
The primary aim of the innate immune system 
is complete extermination of the pathogen 
through this primary inflammatory reaction 
which is then followed by resolution of the 
immunological process by the adaptive immune 
system. 
Activation of complement system  
 Complement system is the second most 
important contributor to the inflammatory 
reaction that occurs in the pathogenesis of 
sepsis. Complement system is made up of small 
proteins that are primarily synthesized by the 
liver and are triggered by the presence of PAMPs 
and DAMPs in the host body via interaction with 
complement components C1q, mannose-binding 
lectin (MBL), and ficolins. Complement system 
can be activated through classical, alternate or 
lectin pathways. However, various intracellular 
(elastase, neutral proteases) and extracellular 
(thrombin, activated clotting factors) proteases 
are known to also generate complement 
proteins such as C3a and C5a, which are small 
protein fragments called anaphylatoxins that 
exert strong proinflammatory effect on leuko- 
cytes, endothelial cells and platelets. C5b 
protein mediates formation of membrane attack 
complex (MAC) that results in lysis of bacteria. 
In addition, complement proteins once activated 
multiply the effects of local immune reactions by 
putting yet more cytokines into play (9).  
Activation of coagulation system and vascular 
endothelium     
 Activation of the coagulation system 
during host-pathogen interaction elicits immune 
defense mechanisms such as induction of 
immune response via protease-activated rece- 
ptors (PARs) activation, release of antimicrobial 
peptides, and recruitment and activation of pha- 
gocytic cells (10). In recent time, the term 
“immunothrombosis” has been hypothesized to 
demonstrate the independence of the innate 
immune and coagulation systems (11). The 
high-level activation of coagulation seen in 
sepsis occurs through the tissue factor-extrinsic 
pathway, resulting in net procoagulant state 
with high risk of microvascular thrombosis. 
Disseminated intravascular coagulopathy (DIC) 
characterized by microvascular thrombosis and 
haemorrhage is one of the most important 
complications of sepsis. Vascular injury in sepsis 
exposes tissue factors to coagulation factors in 
blood, leading to clotting. Endothelial cells and 
macrophages are triggered to express large 
amount of tissue factors by both PAMPs and 
proinflammatory cytokines. Coagulation can 
also be activated in sepsis via the intrinsic 




pathway and stimulate inflammation through 
the kallikrein-kinin system. This is enhanced by 
the reduced activity of the main anticoagulant 
pathways such as the tissue factor pathway 
inhibitor (TFPI), antithrombin, and the protein C 
system (4). 
Interactions of the complement and coagulation 
systems    
 There is an increasing evidence from 
clinical and experimental studies which showed 
that coagulation proteases can activate the 
complement system and vice vasa. In sepsis, 
the functions of coagulation and complement 
systems are closely intertwined. Some compo- 
nents of coagulation and fibrinolytic system such 
as factors IXa, Xa, XIa and thrombin, and the 
central fibrinolytic protease plasmin can convert 
C3 and C5 proteins into C3a and C5a resp- 
ectively. Conversely, C5a and membrane attack 
complex can stimulate exposure of tissue factors 
in endothelial cells due to the structural altera- 
tion caused by the complement products (4,12).  
Vascular endothelial and multiorgan dysfunction
 Following entry of pathogens into the 
host body, platelets and leukocytes migrate to 
the sites of proliferating microbes through the 
vascular endothelium. There is a significant 
nexus between sepsis and disruption of the 
integrity of endothelial barrier. This results in 
exposure of the underlying collagen fibres and 
tissue factors to blood cells in circulation, trig- 
gering activation of platelets and the comple- 
ment system. Thrombin, cathepsin G, matrix 
metalloproteinase (MMP), trypsin and plasmin 
are known activators of protease-activated 
receptors (PARs). Activated PARs cause dys- 
function of endothelial lining via derangement of 
cytoskeletal system, contraction and rounding of 
endothelial cells resulting in disruption of cell-
to-cell contact and vascular hyperpermeability. 
There is usually high level of circulating MMP in 
sepsis (13).      
 The primary cause of death in septic 
shock are either refractory hypotension or multi- 
organ failure. The vascular hyperpermeability 
results in severe hypotension refractory to intra- 
venous fluid resuscitation and vasopressor 
therapy. In addition, there is inability to sustain 
high cardiac output. These are the major causes 
of refractory hypotension (14). Local and 
systemic inflammatory responses cause micro- 
vascular injury that result in organ failure. The 
number of failed organ systems determine the 
outcome of sepsis. About 70% mortality seen in 
sepsis is due to multiorgan (≥3 organ systems) 
failure, and about 18% of patients develop 
respiratory failure. Renal failure resulting from 
renal hypoperfusion, intra-renal shunting, and 
use of nephrotoxic agents (such as antibiotics, 
and radiologic imaging dye) is seen in about 
15% of septic patients (14).      
Platelets activation    
 Recent evidence showed that platelets, 
which are small circulating anucleate cells, play 
a vital role in inflammation and immunity. 
Activated platelets secrete various molecules 
including thromboxane A2 and adenosine di- 
phosphate which have positive feedback effects 
on platelets activation (15). In sepsis, activated 
platelets trigger formation of platelet-leukocyte 
complex, platelet-platelet aggregation as well as 
release of granular cellular components such as 
chemokines, adhesive proteins, coagulation 
factors, mitogenic factors and regulators of 
angiogenesis. Sepsis therefore results in plate- 
lets consumption (thrombocytopenia) with high 
risk of mortality. Also, there is decline in the 
levels of ADAMTS 13 (disintegrin and metallo- 
proteinase with thrombospondin type1 motif 13) 
which is a cleaver of large von Willebrand factor. 
This results in enhanced platelet-endothelium 
(injured) complex, promoting the development 
of vaso-occlusive thrombi in the microvascu- 
lature that contribute to most organ failure seen 
in sepsis (15). Platelet activation in sepsis occurs 
through many mechanisms; thrombin, a coagu- 
lation activation product, is a great activator of 
platelets through the PARs. In the same vein, 
platelets can also be activated by von Willebrand 
factor via binding platelet glycoprotein Ibα (4). 
Anti-inflammatory induction and host 
immunosuppression 
 Induction of anti-inflammatory reaction 
in sepsis is meant to counteract/limit excessive 
and harmful inflammatory process as well as 
stimulate tissue repair. However, immunosup- 
pression results from persistence of anti-inflam- 
matory reactions seen among septic patients 
who required intensive care, a condition referred 
to as “persistent inflammatory, immunosup- 
pression and catabolism syndrome” (6,16). 
Secondary infections with less virulence 
organisms such as Acinetobacter spp., Entero- 
coccus spp., Stenotrophomonas, Candida spp., 
cytomegalovirus and herpes simplex virus 
reactivation can occur as a sequel of persistent 
immunosuppression (17).  
Suppression of innate immune cell functions 
 Neutrophil extracellular traps (NETs), a 
product of neutrophil made up of DNA, histones, 
and neutrophil-derived protease, play an impor- 
tant role in protective immunity through captu- 




ring and killing of microbes. In sepsis however, 
there is defect in neutrophil chemotaxis and 
recruitment to the sites of infection, and 
depressed capacity of neutrophils to produce 
essential effector molecules such as reactive 
oxygen species (ROS) and cytokines. Moreover, 
there is impaired expression of HLA-DR and 
reduced ability to release pro-inflammatory 
cytokines by antigen presenting cells (APCs) 
such as monocytes, macrophages, and dendritic 
cells. This condition is referred to as “immuno- 
paralysis” but their ability to express anti-
inflammatory mediators such as IL-10, is how- 
ever retained (4). 
Suppression of adaptive immune cell functions 
 Significant decline in CD4+ and CD8+ T- 
lymphocytes, B lymphocytes and dendritic cells 
due to programmed cell death (apoptosis) is a 
common finding in sepsis (17,18). In many 
studies with experimental models, admini-
stration of inhibitors of lymphocyte apoptosis 
results in profound improvement in treatment 
outcome. The interaction of programme cell 
death 1 (PD-1), which are immune checkpoint 
(IC) molecules on the surface of T-cells, with its 
corresponding ligands (PD-L1) on the surface of 
antigen presenting cells (APCs) results in high 
degree of immunosuppression of the adaptive 
immune system. The functions of monocytes 
and neutrophils are also inhibited by regulatory 
T cells (Tregs) (17).  
Biochemical, hormonal and organelle 
dysfunctions  
 Some Gram-positive bacteria are capa- 
ble of producing and releasing exotoxins, which 
are often products of plasmids and episomes, 
that act as superantigens (19). The cell wall of 
Gram-negative bacteria are endotoxins, the 
glycoprotein components of which act as toxins, 
that cause pyrexia, vasodilatation, sepsis, and 
endotoxic shock. Bacterial toxins are known to 
play a pivotal role in pathophysiology of sepsis 
(20).  
Oxidation of plasma components  
 Oxidation of the components of the 
blood is one of causes that provide distant 
tissues injury and dysregulation in sepsis. 
Oxidation of plasma components is caused by 
oxygen release to plasma, and it destroys 
humoral regulation of different cells, tissues and 
organs (21). The stimulation of surface rece- 
ptors of erythrocytes by bacteria causes the 
oxygen release.  The higher the concentration of 
oxygen released from erythrocytes to the 
arterial blood, the more severe the sepsis. There 
are many complications which arise as a result 
of the release of a large amount of oxygen.  
Erythrocytes are unable to transport oxygen. 
This results into general multi-organ hypoxia. 
Secondly, the released oxygen is highly 
reactive, and tends to destroy and transform 
plasma proteins, peptides, immune complexes, 
hormones, amino acids, fatty acids, vitamins 
and many other substances necessary for cell 
nutrition, proliferation, protection, and energy 
production and functioning (21).   
Reduction of enzymatic activities and intra- 
vascular coagulation   
 Oxidative changes to proteins can lead 
to diverse functional consequences such as 
inhibition of enzymatic and binding activities, 
increased susceptibility to aggregation (intra- 
vascular coagulation) and proteolysis, increased 
or decreased uptake by cells, and altered 
immunogenicity (22). The most important 
aspect of this oxidation is inactivation of regula- 
tory substances, in particular, hormones inclu- 
ding the pituitary gland hormones (23). 
Impairment of growth hormonal function 
 The growth hormone and insulin-like 
growth factor-1 (IGF-1) axis plays a pivotal role 
in critical illnesses. Derangement in the 
functions of these hormones leads to profound 
changes in metabolism such as protein wasting, 
with loss of skeletal muscle, delay in wound 
healing, and impairment in recovery of organ 
systems (23,24).   
Insulin resistance    
 Inactivation of other proteins such as 
insulin impairs the ability of cells to uptake 
glucose, amino acids, and other essential 
substances. Formation of dityrosine decreases 
and abolishes insulin biological activity (25). 
Insulin is necessary for glucose to enter many 
cell types therefore inactivation of insulin causes 
hyperglycemia, which is one of the metabolic 
derangements that influence sepsis outcome 
(26,27). 
Adrenal and thyroid hormonal insufficiency 
 The oxidation of blood components by 
reactive oxygen species (ROS) released from 
erythrocytes may affect the hypothalamic-
pituitary-adrenal axis (28) resulting in primary 
and secondary adrenal insufficiency in patients 
with sepsis, and is associated with a poor 
outcome (29,30,31). The oxidation of the blood 
components can also affect the hypothalamo-
pituitary-thyroidal axis, leading to inactivation 
of thyrotropin, the thyroid gland hormones 
(triiodothyronine TT3 and thyroxine TT4), and 
their binding proteins. The thyroid hormones 




regulate metabolism and they have impacts on 
sepsis prognosis. The level of TT4 is lower in 
patients with septic shock than in patients 
without septic shock (32,33).   
Generalized vasodilatation and shock  
 Vasopressin (an antidiuretic hormone) is 
also oxidized by the reactive oxygen species 
released from erythrocytes. Vasopressin plays a 
role in circulatory homeostasis and serum 
osmolality. Oxytocin and vasopressin are 
oxidized, with the formation of dityrosine (34). 
Vasopressin oxidation and depletion cause 
vasodilatory shock, a situation associated with 
high mortality (35). Low expression of angio- 
tensin II and angiotensin converting enzyme 
(ACE) are valuable in predicting the mortality of 
patients with severe sepsis (36). Systemic vaso- 
dilatation and arterial hypotension are land- 
marks of septic shock.   
Development of oedema   
 Oxidation of albumin causes hypo- 
albuminemia in sepsis (37,38). Albumin is the 
main determinant of plasma oncotic pressure. It 
plays an important role in modulating the 
distribution of fluids between compartments, 
transport of endogenous and exogenous com- 
pounds, modulation of capillary permeability, 
neutrophil adhesion and activation, haemostasis 
and free radical scavenging (39). Hypoalbumi- 
naemia is a poor prognostic factor in sepsis (40).   
Immunoglobinopathies    
 Reactive oxygen species released from 
erythrocytes also destroys other proteins, inclu- 
ding immune complexes and immunoglobulins, 
particularly IgG and IgM. The initial steps of 
oxidation may change the specificity and avidity 
of immunoglobulins due to chemical alteration 
of the hypervariable region. Oxidation of IgG 
significantly changes the immunoreactivity and 
specificity of IgG fractions (41). Oxidized immu- 
noglobulins have autoimmune and proinflam- 
matory activity (42,43).  Low levels of immuno- 
globulins are frequent in severe sepsis and 
septic shock (44). However, intravenous immu- 
noglobulins (IVIG) as adjunctive therapy have 
not shown benefits in treatment of sepsis (45). 
Anaemia      
 When oxygen is released from erythro- 
cytes into the plasma in arterial blood, they 
cause failure of oxygen delivery to cells resulting 
in tissue hypoxia, which can lead to anaemia 
(46). Many factors contribute to the develo- 
pment of anaemia in sepsis and these include 
blood sampling, decreased erythrocyte synthe- 
sis, bone-marrow suppression, reduced 
production of erythropoietin, and increased 
erythrocyte uptake (47). The main factor of 
anaemia in sepsis is increased destruction of 
erythrocytes caused by; (i) erythrocyte memb- 
rane injury caused by bacteria on the surface of 
erythrocytes; (ii) erythrocyte membrane pores 
with haemoglobin pouring out as a result of 
bacterial penetration into the inner space of 
erythrocyte; and (iii) increased destruction of 
injured erythrocytes and bacteria containing 
erythrocytes in plasma and reticulo-endothelial 
system (RES) particularly spleen (46,48,49).   
Mitochondrial dysfunction   
 Tissue-related hypoxic injury results 
from hypoxaemia, hypoperfusion and cytokine-
mediated mitochondrial dysfunctions, termed 
cytopathic hypoxia (50,51,52). The lack of 
oxygen transforms cell metabolism from aerobic 
to anaerobic. As a result, the Krebs cycle is 
suppressed and with anaerobic metabolism, 
lactic acid accumulation occurs. Lack of oxygen 
delivery to the tissues results in decreased 
cellular metabolism and increase in cellular 
lactate production (42). Elevated lactic acid is a 
marker of suboptimal supply of oxygen to the 
tissues. High levels of lactic acid are associated 
with increased mortality in sepsis (53), and its 
non-clearance in sepsis is a significant indepen- 
dent predictor of death (53,54).    
Clinical manifestations of sepsis 
 The clinical features of sepsis and septic 
shock are non-specific, and include fever or 
hypothermia, tachypnoea, tachycardia, and 
organ dysfunctions which manifest as altered 
mental status, decrease capillary refill, and 
cyanosis (2,55). These presentations are largely 
dependent on the presence or absence of co-
morbidities.  
Haematological manifestations in sepsis   
 Frequent haematological findings seen 
in patient with sepsis include anaemia, leuko- 
cytosis, low platelets, as well as haemostatic 
system activation (56). Patients with sepsis 
often develop anaemia. Factors responsible for 
anaemia in sepsis includes inhibition of erythro- 
poiesis secondary to repressive consequence of 
inflammatory cytokines, impaired iron homeo- 
stasis, reduced life span of the red blood cells 
and haemolysis. Other causes of anaemia in 
patients with sepsis include nutritional deficien- 
cies due to reduced intake, bleeding secondary 
to disseminated intravascular coagulopathy and 
frequent phlebotomy (57). The haematologic 
manifestations are varied and include anaemia, 
leukopaenia, leukocytosis and DIC.  




Anaemia    
 The effect of pro-inflammatory cyto- 
kines on erythropoietin production has been 
reported. Such cytokines include TNF-α, IL-1 
and IL-6. Apoptosis of the colony forming unit 
erythroid and the burst forming erythroid by 
interferon gamma (IF-γ) and IL-1 contributes 
significantly to anaemia seen in patients with 
sepsis. Bleeding in this category of patients 
secondary to DIC and gastrointestinal bleeding 
from stress ulcers (57) could cause anaemia.  
 Iron metabolism is impaired in patient 
with sepsis. The altered iron metabolism is 
secondary to increased levels of hepcidin (58), 
which is produced mainly in the liver, and its 
level is elevated secondary to increased 
expression of IL-6 in patients with sepsis (20). 
There is also inhibition of iron release from the 
RES, inhibition of iron absorption from the 
intestinal mucosa as well as inhibition of iron 
incorporation into maturing erythrocyte, with 
increased levels of hepcidin, leading to iron 
deficit erythropoiesis (59). Sepsis reduces 
erythrocyte lifespan by causing alteration in 
erythrocyte metabolism, and by reducing 2,3-
bisphosphoglycerate, it can cause significant 
increase in production of deformed red cells. The 
cumulative effects of these alterations affect the 
membrane of the red blood cells, and reduce its 
survival (60).  
Neutrophilia     
 The major haematologic findings in 
patients with sepsis are leukocytosis and 
neutrophilia. These are usually accompanied 
with peripheral blood film features of toxic gra-
nulation of neutrophils and vacuolations. Left 
shift are often seen, in which maturing myeloid 
cells, including myelocytes, metamyelocytes 
and band forms, appear in the peripheral blood. 
Sometimes few promyelocytes and blasts are 
observed (61). High leucocyte count (up to 
50x109/L) referred to as leukaemoid reaction, 
may be seen in some bacteria sepsis and may 
need to be differentiated from chronic myeloid 
leukaemia (CML). One of the criteria for 
diagnosis of sepsis includes left shift, with 
immature myeloid cells greater than 10. 
Neutropaenia has also been noted in some 
patients with sepsis, usually in the elderly and 
young children (62). 
Lymphopaenia      
 Lymphopaenia has been documented in 
patients with sepsis, usually due to apoptosis of 
the lymphocytes and lymphocyte redistribution 
from the compartment of blood to tissues of 
lymphoid origin (62).  
Thrombocytopaenia                         
 Thrombocytopaenia (low platelet count) 
occurs commonly in patients with sepsis. The 
cause and contributing factors to thrombocyto- 
paenia in patients with sepsis include reduced 
platelets production, consumption of platelets in 
DIC, platelet destruction via immune mediated 
mechanism, and haemodilution (63). Aggre- 
gation of platelets as well as its attachment to 
the endothelium and leukocytes may contribute 
to thrombocytopaenia that is observed in 
patients with sepsis. Immunoglobulin of the IgG 
class has been associated with immune 
mediated thrombocytopaenia and reported in up 
to 30%-40% of the patients with sepsis (64). 
 Reported findings of coagulopathy in 
patients with sepsis are common. The spectrum 
may range from subtle initiation of coagulation 
cascade to DIC. Patients with sepsis may 
present with venous forms of thromboembolism 
or DIC. Contributory factors to coagulopathy in 
patients with sepsis include increased tissue 
factor expression, endothelial cell dysfunction 
with inhibition of the natural anticoagulant 
process, and inhibition of the fibrinolytic 
pathways (65,66). 
Disseminated Intravascular Coagulation (DIC) 
 The maintenance of steady blood flow is 
enhanced by balance between the procoagulant 
and anticoagulant systems. Coagulopathy in 
patients with sepsis is associated with increased 
levels of procoagulant proteins and reduced 
levels of naturally occurring anticoagulants. 
There is increased tissue factor expression in 
patients with sepsis, which is responsible for 
initiation of the coagulation cascade (67). The 
natural anticoagulant system is impaired in 
sepsis, with reduced levels of anti-thrombin III 
and protein C. Thrombin production is increased 
with subsequent generation of fibrin, and with 
consumption of the coagulation factors, DIC 
may occur (68). 
Biochemical changes in sepsis 
 Inflammatory cytokines (IL-6, IL-8 and 
TNF-α) are elevated in patients with sepsis and 
septic shock, so are the levels of nitrous oxide 
and lactic acid (69). Only elevated levels of IL-6 
and IL-18 are associated with increased morta- 
lity in patients with sepsis and septic shock, 
while elevated levels of TNF-α, lactate and 
nitrous oxide (though observed in patients with 
sepsis) are not associated with increased 
mortality (58).  Creatinine levels are only 
elevated when there is an associated liver 
damage.  




 Biomarkers, which are genes, molecules 
or other host factors help in the identification of 
health and disease processes. Biomarkers of 
importance in patients with sepsis can be 
grouped into diagnostic and prognostic markers. 
Diagnostic biomarkers provide sensitive and 
specific information that can be used to 
differentiate sepsis from all other forms of non-
infectious critical illnesses. This enhances anti- 
biotic stewardship program as it helps reduce 
unnecessary use of antibiotics where they are 
not required (55). However, prognostic bio- 
markers are used to monitor patients with sepsis 
on treatment and also in predicting prognosis 
including complications.  
 Monocyte anergy which presents with 
decreased expression of monocyte HLA-DR, is 
has been reported to be an independent 
predictor of poor prognosis in patient with 
sepsis. Recently, the term theranostics was 
introduced and entails biomarker tests that help 
in the selection and monitoring of treatment 
response, a step towards personalized medicine. 
According to the Surviving Sepsis Campaign 
(SSC) guidelines, procalcitonin is the only bio- 
marker with potential usefulness in the choice of 
antibiotics in critically ill patients. Other bio- 
markers with lower sensitivity and specificity 
include C-reactive protein (CRP), IL–6, LPS 
binding proteins (LBPs) and lactate (5,55).  
Complications of sepsis             
 The main complication of sepsis is septic 
shock. However, there are other sets of possible 
complications, which include kidney failure, 
multiple organ failure, and heart dysfunction. 
Dialysis may be needed temporarily or 
permanently if the kidneys fail, and death can 
occur from multiple organ systems dysfunctions 
and failure. Stroke due to low blood pressure on 
the brain and cognitive decline have been 
reported in some patients with septic shock 
(70).        
Management of sepsis 
 The major principles of management of 
sepsis include; timely identification of sepsis 
features, titrated fluid resuscitation, adequate 
source control, obtaining blood culture samples 
prior to commencement of antimicrobials (this is 
the gold standard for diagnosis of sepsis), and 
organ support (77).  
Clinical assessment and management 
 In the management of sepsis, clinical 
assessment is carried out initially to detect the 
risk factors for infection. These include age, 
chronic disease, immunosuppressive therapy, 
AIDS, pre-existing co-morbidities such as 
diabetes mellitus (DM), renal failure, and 
bleeding disorders. The aim of physical exami- 
nation is to identify the possible foci of infection. 
The vital signs are used to evaluate clinical 
improvement during hospital admission (77,78).
 Serious cellular, circulatory, and meta- 
bolic abnormalities occur in patients with septic 
shock. Clinically, patients with septic shock 
require a vasopressor to maintain mean arterial 
blood pressure of ≥ 65 mmHg and serum lactate 
level >2 mmol/L (>18 mg/dl) in the absence of 
hypovolemia. A patient with suspected infection 
can be rapidly identified as being more likely to 
have poorer outcomes typical of sepsis if they 
have at least 2 of the following clinical criteria 
which together constitute a new bedside clinical 
score termed quick SOFA (qSOFA); respiratory 
rate ≥22/min; altered consciousness (Glasgow 
coma score < 13) and systolic blood pressure 
(SBP) ≤ 100 mm/Hg (78).   
 The particular site of infection in the 
body should be identified as soon as possible, at 
least within 6 hours of presentation. This is 
referred to as source control (79), and helps 
define early goals of management e. g. presence 
of invasive devices suspected to be source of 
infection can be promptly removed. Distinction 
should be made between sepsis and septic shock 
in order to guide management of patient. During 
the first 6 hours of presentation, initial 
resuscitation involves achieving the following 
goals; central venous pressure of 8-12 mmHg, 
mean arterial pressure of 65 mmHg, urine 
output of 0.5 ml/kg/Hr, and central venous/ 
mixed venous oxygen saturation of 70%/65% 
respectively.     
 The fluid of choice for initial resusci- 
tation of patients with sepsis/septic shock is 
crystalloids with the aim of achieving a minimum 
of 30 ml/kg of crystalloids (4). Blood culture 
samples and urine culture or sputum samples 
should, as much as possible, be obtained before 
administration of antibiotics. However, treat- 
ment should not be delayed if this is not 
possible. Intravenous antibiotics should be 
administered within the first hour of recognition 
of sepsis/septic shock (3). A broad-spectrum 
antibiotic that can penetrate the tissues in 
adequate concentration should be used. If the 
cause of sepsis/septic shock is suspected to be 
of viral origin, appropriate antiviral therapy (if 
available for the virus) should be initiated (70). 
Laboratory assessment                    
Blood culture                
 This is the “gold standard” for diagnosis  




of sepsis. A minimum of two sets of blood 
cultures (aerobic and anerobic) should be 
collected as much as possible before initiating 
antimicrobial therapy. Urine, pus, ascitic fluid, 
pleural fluid, cerebrospinal fluid, and other body 
fluids may be collected as well.    
Ancillary laboratory studies   
 Other laboratory studies essential for 
diagnosis and monitoring of progress of patients 
with sepsis (58,80) include; complete blood 
count (total and differentials), electrolytes, urea 
and creatinine (E, U, Cr), prothrombin time,  
liver function tests, arterial blood gas analysis,  
urinalysis, chest X-ray (to identify source of 
pulmonary infection and respiratory distress), 
computerized tomography (CT) scan, positron 
emission tomography (PET-CT) and magnetic 
resonance imaging (MRI) techniques to identify 
source of primary infections   
Estimation of biomarkers of sepsis  
 In recent years, biomarkers that allow 
early diagnosis of sepsis have been sought for in 
order to allow early diagnosis of sepsis, since 
culture-based diagnosis is slow. These bio- 
markers include C-reactive protein, lactate and 
procalcitonin. C-reactive protein (CRP) is an 
acute phase protein produced by the liver and 
alveolar macrophages. Its level increases after 
trauma and inflammation. Bacterial infections 
are powerful stimuli which produce rapid rise in 
CRP levels in few hours. Its production is 
stimulated by IL-1, IL-6 and TNF-α. Changes in 
plasma levels of CRP are useful in diagnosis/ 
prognosis of infection, a fall in plasma levels 
indicates infection resolution and its assay is less 
expensive (71).      
 Procalcitonin (PCT) has been popularly 
referred to as the most useful marker of severe 
systemic inflammation (72). It is normally found 
in blood at very low level but its production can 
be stimulated by inflammatory cytokines and 
bacterial endotoxins, causing its release in 
higher concentration in response to infection 
and to systemic infections in patients with viral 
disease (73). It provides an indicator of risk of 
sepsis, the higher the level of PCT, the greater 
the likelihood of systemic infection and sepsis. 
It is regarded as the most sensitive biomarker 
to help diagnose bacterial sepsis. This can help 
allow earlier diagnosis of sepsis and better 
monitoring of its progression.   
 Lactate is another biomarker of sepsis. 
An increase in its level implies poor tissue 
perfusion and progression to organ dysfunction 
and are related to or associated with increases 
mortality rate from 35% to 70%. The use of 
lactate as a marker for diagnosis, prognosis and 
treatment of tissue hypoxia in septic shock has 
been established to be important. Therefore, a 
patient with sepsis and significant lactic acidosis 
should receive early antibiotics, haemodynamic 
monitoring, and adequate resuscitation (73). 
Absence of lactate clearance in the blood 
predicts death of sepsis patient. A high level of 
lactate may be a manifestation of organ dys- 
function because its clearance is dependent on 
the liver and kidney functions. Lactate has been 
reported to be very useful as a prognostic 
indicator of state of septic shock (74,75,76).  
 Venous-arterial pressure difference 
(dPCO2) is another important biomarker of 
septic shock. The measurement of dPCO2 is a 
good prognostic indicator in septic shock, as it 
provides an index of tissue oxygenation (76).    
Sepsis treatment care bundles 
 The mortality rate in septic shock is 
high. Over the years, due to the high incidence 
and mortality rate of sepsis and septic shock, 
the Surviving Sepsis Campaign (SSC) was set 
up by a group of international critical care and 
infectious disease experts. The SSC third revised 
guidelines, published in 2017, aims to improve 
the outcome of sepsis and septic shock (55).  
 In the revised guideline, the previous 6- 
hour and 3-hour bundles have been compressed 
into a one-hour bundle with 5 steps initiated at 
time zero of patient presentation. The one-hour 
Surviving Sepsis Campaign Bundle of Care 
(81,82) includes; (i) measure lactate level with 
repeat measurement if baseline lactate is                     
> 2 mmol/L; (ii) obtain blood culture samples 
prior to initiation of antibiotics; (iii) use of 
broad-spectrum antibiotics; (iv) commence 
rapid administration of crystalloid at 30 ml/kg 
for hypotension or lactate level of ≥ 4 mmol/L; 
and (v) administer vasopressors if patient 
remains hypotensive during or after resusci- 
tation to ensure mean arterial pressure (MAP) at 
≥65mmHg. The “time-zero” or “time of presen- 
tation” is defined as the time of triage at the 
emergency department or if presenting from 
another care facility, from the earliest chart 
annotation consistent with all elements of sepsis 
or septic shock ascertained through chart review 
(82). 
Discussion: 
 About 49 million cases of sepsis, and 11 
million sepsis-related deaths were reported 
globally in the year 2017 (3). These sepsis-
related deaths constitute about 20% of all 
deaths globally. Sepsis is often seen in patients 
with background of previous medical conditions, 




and are caused by opportunistic organisms from 
patient’s own microbiota (55,83). The SOFA 
score, consisting of altered respiratory rate of 22 
breaths/minute or more, altered mental status, 
and systolic blood pressure of 100mmHg or less, 
is designed to measure the severity and 
prognosis from sepsis and septic shock (55). 
 Sepsis is a life-threatening organ dys- 
function caused by dysregulated host response 
to infection. Clinically, organ dysfunction is 
identified by an acute increase in the SOFA score 
of two or more points. A patient with SOFA score 
of ≥2 has an attributable 2 - 25-fold increased 
risk of mortality compared to a patient with ˂ 2 
SOFA score (61).  The most commonly isolated 
Gram-positive bacteria are Staphylococcus 
aureus, Staphylococcus epidermidis, Strepto- 
coccus pneumoniae, and Enterococcus spp., 
while the most commonly implicated Gram-
negative bacteria causes are Escherichia coli, 
Klebsiella spp., Pseudomonas spp., and Acineto- 
bacter spp. Among patients with background co- 
morbidity or hospital-acquired sepsis, the 
isolated pathogens are mostly multidrug 
resistant staphylococci, Pseudomonas, Acineto- 
bacter and Candida spp (84). Other organisms 
such as Burkholderia pseudomallei and Salmo- 
nella enterica have been reported (85,86).
 The pathophysiology of sepsis is a 
complex event involving hyperinflammatory 
syndrome that results in ‘cytokine-chemokine 
storm’, anti-inflammatory response and host 
immunosuppression that can lead to secondary 
infection, and a variety of host biochemical, 
hormonal and organelle dysfunctions (4,8,16, 
17,18,19,20). The clinical symptoms and signs 
of sepsis and septic shock are tachypnoea, fever 
or hypothermia, tachycardia, and organ dys- 
functions manifested as altered mental status, 
decrease capillary refill, and cyanosis (2,4). 
Frequent haematological findings seen in patient 
with sepsis include anaemia, leukocytosis, 
thrombocytopaenia and activation of haemo- 
static system (56). Anaemia in sepsis is mainly 
due to increased levels of pro-inflammatory 
cytokines such as TNF-α, IL-1 and IL-6, apo- 
ptosis of the colony forming unit erythroid and 
burst forming erythroid by IF-γ IL-1, and 
impairment of iron metabolism secondary to 
increased levels of hepcidin (57,58). 
 Leukocytosis and neutrophilia are also 
major findings in patients with sepsis, along with 
peripheral blood film features of toxic granu- 
lation of neutrophils and vacuolations.  Left shift 
with maturing myeloid cells, myelocytes, meta- 
myelocytes and band forms, appear in the 
peripheral blood. Sometimes few promyelocytes 
and blasts are visible (61). High leucocyte count 
(up to 50x109/L) referred to as ‘leukaemoid 
reaction’, may be seen in some bacteria sepsis 
and should to be differentiated from chronic 
myeloid leukaemia (63).    
 Thrombocytopaenia that is observed in 
patients with sepsis is due to the aggregation of 
platelets, as well as its attachment to the 
endothelium and leukocytes. Immunoglobulin of 
the IgG class has also been associated with 
immune mediated thrombocytopaenia, and was 
recorded in up to 30%-40% of the patients with 
sepsis (64). Inflammatory cytokines (IL-6, IL-8, 
IL-10 and TNF-α) are elevated in patients with 
sepsis and septic shock, so are levels of nitrous 
oxide and lactic acid (69).  Elevated IL-6, IL-8 
and IL-18 levels are associated with increased 
mortality in patients with sepsis and septic 
shock but elevated levels of TNF-α, lactate and 
nitrous oxide (though observed in patients with 
sepsis) are not associated with increased morta- 
lity, and creatinine levels are only elevated when 
there is an associated liver damage (58). The 
main complications of sepsis are septic shock, 
multiple organ failures, DIC and cardiac dys- 
function. Death occur when multiple organ 
systems become dysfunctional and shutdown. 
Stroke due to low blood pressure on the brain 
and cognitive decline can also complicate septic 
shock (72).     
 Clinical assessment is based on the risk 
factors for infection which include age, under- 
lying chronic disease, immunosuppressive 
therapy, HIV/AIDS, pre-existing co-morbidities 
such as diabetes mellitus (DM), renal failure, 
and bleeding disorders. There is an urgent need 
to identify the possible foci of infection, and vital 
signs are measured and used to evaluate clinical 
improvement during admission (77,78). A 
patient with suspected infection can be rapidly 
identified as being more likely to have poorer 
outcomes from sepsis if they have at least 2 
SOFA score (qSOFA); respiratory rate ≥22/min, 
altered consciousness with GCS score of < 13, 
and systolic blood pressure (SBP) of 100mm/Hg 
(78,79,81).    
 Treatment of sepsis is based on intra- 
venous fluid administration and correction of 
acidosis, identification of primary site and agent 
of infection, administration of antimicrobial 
agents based on the local susceptibility pattern 
of the causative agents, and implementing the 
1-hour ‘Sepsis-3 Bundles’ or ‘The SSC 2018 
Update’ as described by the Surviving Sepsis 
Campaign, depending on the clinical assessment 
of the patient (80,81,82,88). 
Conclusion: 
 Sepsis is a medical emergency resulting 
from infection by bacteria, fungi and viruses 




including severe acute respiratory syndrome 
coronavirus-2 (SARS-COV-2), the aetiology of 
the ongoing COVID-19 pandemic. The SOFA 
score is used for the initial assessment and 
monitoring of such patients, and management is 
based on identification of primary site and agent 
of infection, intravenous fluid administration and 
correction of acidosis, administration of anti- 
microbial agents determined by the local susce- 
ptibility pattern of the causative agents, and 
implementation of the 1-hour ‘Sepsis-3 Bundles’ 
or ‘The SSC 2018 Update’ described by the 
Surviving Sepsis Campaign, depending on the 
clinical assessment of the patient. 
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